

1 **COA5 has an essential role in the early stage of mitochondrial complex IV**
2 **assembly**

3

4 Jia Xin Tang^{1#}, Alfredo Cabrera-Orefice², Jana Meisterknecht², Lucie S. Taylor^{1,3},
5 Geoffray Monteuis⁴, Maria Ekman Stensland⁵, Adam Szczepanek¹, Karen Stals⁶,
6 James Davison^{7,8}, Langping He³, Sila Hopton³, Tuula A. Nyman⁵, Christopher B.
7 Jackson⁴, Angela Pyle¹, Monika Winter^{1,9}, Ilka Wittig² and Robert W. Taylor^{1,3*}

8

9

10 ¹ Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of
11 Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

12 ² Functional Proteomics Center, Institute for Cardiovascular Physiology, Goethe University,
13 Frankfurt am Main, Germany

14 ³ NHS Highly Specialised Rare Mitochondrial Disorders Service, Newcastle upon Tyne
15 Hospitals, NHS Foundation Trust, Newcastle upon Tyne, UK

16 ⁴ Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of
17 Helsinki, Helsinki, Finland

18 ⁵ Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo
19 University Hospital, Oslo, Norway

20 ⁶ Department of Molecular Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter,
21 UK

22 ⁷ Department of Paediatric Metabolic Medicine, Great Ormond Street Hospital for Children
23 NHS Foundation Trust, UK

24 ⁸ National Institute of Health Research, Great Ormond Street Hospital Biomedical Research
25 Centre, London, UK

26 ⁹ Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria
27 University, Newcastle upon Tyne, UK

28

29

30

31 # **Present address:** Department of NanoBiophotonics, Max Planck Institute for
32 Multidisciplinary Sciences, Göttingen, Germany

33

34

35

36

37

38

39

40

41

42

Character count: 50 916

43 **Abstract**

44 Pathogenic variants in cytochrome *c* oxidase assembly factor 5 (COA5), a proposed
45 complex IV (CIV) assembly factor, have been shown to cause clinical mitochondrial disease
46 with two siblings affected by neonatal hypertrophic cardiomyopathy manifesting a rare,
47 homozygous COA5 missense variant (NM_001008215.3: c.157G>C, p.Ala53Pro). The most
48 striking observation in the affected individuals was an isolated impairment in the early stage
49 of mitochondrial CIV assembly. In this study, we report an unrelated family in who we have
50 identified the same COA5 variant with patient-derived fibroblasts and skeletal muscle
51 biopsies replicating an isolated CIV deficiency. A CRISPR/Cas9-edited homozygous COA5
52 knockout U2OS cell line with similar biochemical profile was generated to interrogate the
53 functional role of the human COA5 protein. Mitochondrial complexome profiling pinpointed a
54 role for COA5 in early CIV assembly, more specifically, its involvement in the stage between
55 MTCO1 maturation and the incorporation of MTCO2. We therefore propose that the COA5
56 protein plays an essential role for the biogenesis of MTCO2 and its integration into the early
57 CIV assembly intermediate for downstream assembly of the functional holocomplex.

58

59 **Keywords:** COA5 / Complex IV / complexome profiling / mitochondria / OXPHOS assembly

60 Introduction

61 Mitochondria synthesise cellular energy in the form of adenosine triphosphate (ATP)
62 via oxidative phosphorylation (OXPHOS), comprising four respiratory chain complexes and
63 the F₁F₀ ATP synthase. Cytochrome *c* oxidase (COX), also known as complex IV (CIV), is
64 the terminal electron acceptor of the respiratory chain which catalyses the reduction of
65 molecular oxygen to water. CIV couples this redox reaction to the translocation of protons
66 across the inner mitochondrial membrane, thus contributing to the generation of the proton-
67 motive force harnessed by the F₁F₀ ATP synthase to generate ATP.

68 CIV is comprised of 14 protein subunits of dual genetic origin; the three core subunits
69 (MTCO1, MTCO2 and MTCO3) are all mitochondrially-encoded while the remaining subunits
70 are encoded by the nuclear genome (Kadenbach, 2017; Wikström *et al*, 2018). Remarkably,
71 CIV possesses two redox active copper centres (binuclear Cu_A and mononuclear Cu_B
72 centres) and two haem groups (haem *a* and haem *a*₃) (Wikström *et al.*, 2018). These redox
73 active cofactors are crucial for electron transfer within CIV which entails: (i) the receipt of
74 electrons from reduced cytochrome *c* by the Cu_A centre in the MTCO2 subunit, (ii)
75 subsequent delivery of the electron by the haem *a* group in membrane-spanning MTCO1
76 subunit to (iii) the oxygen-reducing haem *a*₃-Cu_B centre (Belevich *et al*, 2006; Kirchberg *et al*,
77 2012; Muramoto *et al*, 2010). These reactions result in the pumping of a total of four protons
78 per oxygen molecule into the mitochondrial intermembrane space (IMS).

79 As a consequence, an intricate assembly machinery has been generally described
80 for complex IV on a modular basis centred around the three catalytic subunits: MTCO1,
81 MTCO2 and MTCO3 with over 20 unique assembly factors of CIV having been characterised
82 to date (Signes & Fernandez-Vizarra, 2018; Vidoni *et al*, 2017; Watson & McStay, 2020).
83 These assembly factors are not only involved in the sequential incorporation of the protein
84 subunits but also crucial for auxiliary processes such as translational regulation, protein
85 stabilisation as well as the insertion of cofactors and prosthetic groups (Povea-Cabello *et al*,
86 2024; Watson & McStay, 2020).

87 The cytochrome c oxidase assembly factor 5 (COA5) gene (RefSeq:
88 NM_001008215.3), previously denoted as *C2orf64*, was first reported in humans when a
89 homozygous missense variant (c.157G>C, p.Ala53Pro) in this gene was shown to cause
90 mitochondrial disease. Biochemical studies of patient-derived fibroblasts revealed isolated
91 COX deficiency, more specifically the accumulation of CIV assembly intermediates and
92 decreased levels of fully assembled CIV holocomplexes, leading the authors to hypothesise
93 that COA5 is involved in the early stages of CIV assembly (Huigsloot *et al*, 2011). However,
94 earlier studies carried out using the yeast orthologue of human COA5 protein, Pet191, also
95 suggested a putative role in CIV assembly but with no impact on COX translation and copper
96 metalation of the protein (Khalimonchuk *et al*, 2008; McEwen *et al*, 1993; Tay *et al*, 2004).
97 Interestingly, contradicting evidence have been published with regards to the mitochondrial
98 localisation of the Pet191 protein despite being a member of the twin CX₉C protein family
99 that are often found to be dependent on the Mitochondrial Intermembrane space Import and
100 Assembly (MIA) pathway (Bragoszewski *et al*, 2013; Khalimonchuk *et al.*, 2008).

101 Here we present an unrelated family in which a clinically affected child harbours the
102 identical *COA5* missense variant, identified by trio whole exome sequencing (Longen *et al*).
103 We generated a CRISPR/Cas9-mediated *COA5* knockout (*COA5*^{KO}) cell line to elucidate the
104 role of *COA5* in CIV assembly and its implications on mitochondrial health and disease,
105 utilising an array of biochemical tools including mitochondrial complexome profiling.

106

107 Results

108 *Clinical summary and genomic studies*

109 A female neonate born to second cousin parents presented with tachypnoeic
110 episodes on the first day of life. Blood lactate was elevated at variable levels between 2.5 to
111 11 mmol/L. Clinical examination detected hyperdynamic precordium with loud second heart
112 sound and subsequent echocardiography indicated significant biventricular hypertrophic
113 cardiomyopathy with septal hypertrophy and non-compaction appearance of the myocardium.
114 Due to worsening respiratory distress, she was intubated and given inotropic support after
115 birth before being discharged. Liver function tests were abnormal with increased
116 echogenicity of liver on ultrasound. Neuroimaging of the brain was normal. Focused
117 metabolic biochemical investigations identified elevated urinary lactate and ethylmalonic acid.
118 Clinical care was directed to symptomatic management only when a presumptive diagnosis
119 of mitochondrial disorder with hypertrophic cardiomyopathy was made having identified
120 evidence of significant complex IV activity deficiency on muscle biopsy as detailed below.
121 She was readmitted several weeks later with further deterioration of respiratory distress
122 concurrent with a rhinovirus infection, poor cardiac function and severe lactic acidosis and
123 sadly passed away.

124 Molecular genetic testing eliminated pathogenic mitochondrial DNA (mtDNA) variants
125 following a complete analysis of the mitochondrial genome. Trio whole exome sequencing
126 conducted at the Exeter Genomics Laboratory identified a previously reported COA5 variant
127 (c.157G>C, p.Ala53Pro), confirming both parents to be heterozygous carriers (**Fig 1A**)
128 (Chen *et al*, 2023; Huigsloot *et al.*, 2011). The homozygous COA5 missense variant has
129 been recorded on ClinVar as a pathogenic variant associated with isolated COX deficiency
130 (<https://www.ncbi.nlm.nih.gov/clinvar/variation/31087/>). The c.157G>C COA5 variant causes
131 an amino acid change from alanine to proline at position 53 of the COA5 protein, which is
132 located within the CX₉C domain that has suggested linkage to mitochondrial protein
133 localisation (Gladyck *et al*, 2021) (**Fig 1B**). The alanine residue is not conserved across

134 species and is only shared between human and zebrafish (**Fig 1B**). Whilst the application of
135 several *in silico* pathogenicity prediction tools suggested the c.157G>C COA5 variant to be
136 damaging, the REVEL meta-predictor score was below the recommended threshold for this
137 variant, necessitating further study (Ioannidis *et al*, 2016).

138 ***Patient-derived muscle biopsies and fibroblasts displayed isolated complex IV***
139 ***deficiency***

140 Histochemical analysis of skeletal muscle cryosections from the patient indicated a
141 moderate CIV deficiency in all fibres (**Fig 2A**). This was corroborated by quadruple OXPHOS
142 immunofluorescence assay which showed a marked loss of MTCO1 immunoreactivity (**Fig**
143 **2B**) while NDUFB8 (complex I subunit) protein levels were normal (Ahmed *et al*, 2017). The
144 direct measurement of respiratory chain enzyme activities in patient-derived fibroblasts also
145 indicated a severe and isolated complex IV deficiency in the COA5 patient muscle sample
146 (**Fig 2C**).

147 ***Implications of the homozygous COA5 variant on the steady-state level and assembly***
148 ***of complex IV***

149 To characterise the pathogenicity of the COA5 missense variant, SDS-PAGE and
150 BN-PAGE were used to delineate its impact on OXPHOS protein steady-state levels and
151 assembly. Decreased steady-state levels were only observed in CIV subunit, MTCO2 while
152 other OXPHOS complex subunits were unaffected in whole cell lysates of both patient-
153 derived fibroblasts and skeletal muscle biopsy (**Figs 3A and 3C**). Likewise for BN-PAGE,
154 only complex IV assembly was impaired in patient-derived fibroblasts and skeletal muscle
155 whereas the remaining four OXPHOS complexes (CI, CII, CIII and CV) were unaffected,
156 similar to age-matched controls (**Figs 3B and 3D**). These observations were further
157 supported by proteomic analysis of the immortalised patient fibroblasts which highlighted the
158 isolated CIV deficiency. CIV protein subunits exhibited a statistically significant decrease in

159 protein abundance up to almost four-fold while CI, CII, CIII and CV protein abundance
160 remained unchanged (**Fig 3E**).

161 ***Functional characterisation of COA5 in a CRISPR/Cas9 knockout cell line***

162 Both the primary and immortalised patient fibroblasts harbouring the homozygous
163 c.157G>C COA5 variant displayed arrested cell growth in culture, likely owing to the severe
164 CIV deficiency and therefore making further experimentation challenging in primary
165 fibroblasts. To enable in-depth characterisation of the functional role and the implicated
166 pathogenicity of COA5, CRISPR/Cas9 gene editing was utilised to generate a homozygous
167 COA5 knockout (COA5^{KO}) in the immortalised human U2OS cell line for a more stable
168 cellular model system. The COA5^{KO} cell line generated contained a homozygous 7 base pair
169 deletion in the COA5 gene (c.287_290+3del, p.Val61del) as verified by Sanger sequencing
170 (**Figure EV1**). Western blot analyses of the COA5^{KO} cell line also confirmed an isolated CIV
171 defect in terms of protein steady-state level (**Fig 4A-B**) as well as OXPHOS complex
172 assembly (**Fig 4C**), successfully mimicking the biochemical phenotype observed in patient-
173 derived biopsies. Interestingly, an accumulation of the complex II subunit, SDHA protein at
174 around 70 kDa was also observed on BN-PAGE analysis of the COA5^{KO} cell line which was
175 absent in the isogenic control (**Fig 4C**).

176 ***Mitochondrial Complexome Profiling of COA5^{KO} cell line***

177 To define the functional involvement of COA5 in CIV assembly, mitochondrial
178 complexome profiling, which combines BN-PAGE and tandem mass spectrometry (LC-
179 MS/MS), was used to determine the presence and arrangement of the OXPHOS system and
180 related protein complexes (Alahmad *et al*, 2020; Alston *et al*, 2018; Cabrera-Orefice *et al*,
181 2022; Lobo-Jarne *et al*, 2020). This technique enables visualisation of the specific stage of
182 CIV assembly impacted when COA5 is absent using the COA5^{KO} cell line and potentially
183 uncovering interacting partners of the COA5 protein to elucidate its functional role.

184 First, complexome profiling (**Fig 5**) confirmed our result on BN-PAGE_(**Fig 4**). An
185 increased abundance of respiratory supercomplexes containing complexes I and III₂ (S₀:
186 I+III₂) was observed in the COA5^{KO} cell line (**Fig 5, right panel**). As observed in BN-PAGE
187 analysis of the COA5^{KO} mitochondrial extracts (**Fig 4C**), accumulation of the SDHA subunit
188 of CII was also detected by complexome profiling at a molecular size of approx 80 -100 kDa
189 (native calibration of soluble complexes), but not in the isogenic control (highlighted in
190 orange box in **Fig EV2, right panel**). Interesting, SDHAF1 and SDHAF2 comigrate at the
191 same range indicating an assembly intermediate (**Fig EV3, right panel, orange box**). When
192 assessing complex III subunits, a complete loss of the supercomplexes III₂+IV (S₀) was
193 observed in the COA5^{KO} cell line (**Fig 5**). Of all the OXPHOS complexes, only complex V
194 content and assembly were unaffected (**Fig 5**).

195 Next, we had a closer look to complex IV subunits and assembly factors. We noted a
196 complete loss of the COA5 protein as the respective 12 kDa protein was not detected in the
197 knockout cell line but clearly present in the isogenic control as highlighted (**Fig 6A,**
198 **highlighted in yellow**). More importantly, the accumulation of early CIV assembly
199 intermediates (**Fig 6A, right panel, green boxed subunits and assembly factors**) and the
200 loss of fully assembled CIV holocomplexes were observed in contrast to the isogenic control
201 cell line (**Fig 6A, left panel**). Interestingly, subunits of the MTCO1 and MTCO2 modules
202 accumulate in this intermediate, suggesting that despite the lack of subunits in the individual
203 modules, further assembly is already taking place. This provides supporting evidence to the
204 putative role of COA5 as an assembly factor in early stages of complex IV biogenesis and
205 the isolated CIV defect resulting from the loss of COA5 protein as observed in biochemical
206 studies of patient-derived cells and tissues (**Fig 3**).

207

208 Discussion

209 This study identified the previously reported c.157G>C, p.Ala53Pro COA5 variant in
210 another family. The isolated CIV deficiency associated with the COA5 variant was observed
211 in the patient fibroblasts and skeletal muscle biopsy, firmly supported by unbiased proteomic
212 profiling of the immortalised COA5 patient fibroblasts as the biochemical signature of COA5
213 deficiency. Most importantly, a CRISPR/Cas9 COA5^{KO} cell line enabled further interrogation
214 via complexome profiling, narrowing down the involvement of COA5 protein to a specific
215 stage of CIV biogenesis involving MTCO2 stabilisation and its incorporation into the MTCO1-
216 containing subcomplex. This study pinpoints specific questions that arise with regards to the
217 functional role of the COA5 protein as a CIV assembly factor, which we elaborate on further
218 below.

219 Given that the rare c.157G>C, p.Ala53Pro variant was found only in two incidences
220 where both patients were of identical ethnicity, this could point towards the likelihood of the
221 variant being a founder pathogenic variant within this population. However, this would
222 require further verification through haplotype analysis, necessitating access to patient-
223 derived samples from the previous case. Importantly, overlapping clinical and biochemical
224 phenotypes were observed between the proband in this study and the previously reported
225 patient by Huigsloot and colleagues back in 2019 (Huigsloot *et al.*, 2011), further
226 strengthening the claim that the c.157G>C (p.Ala53Pro) COA5 variant is pathogenic and
227 causative of an isolated mitochondrial complex IV deficiency, associated with loss of steady-
228 state COX proteins and a COX assembly defect in isolation (**Fig 2A-C** and **Fig 3**).

229 To further characterise the functional impact of COA5, we generated a
230 CRISPR/Cas9-mediated knockout. The COA5^{KO} cells successfully replicated the isolated
231 complex IV deficiency observed in the reported patients by indicating a loss of MTCO2
232 protein but not MTCO1 detected at comparable levels to the isogenic control on SDS-PAGE
233 (**Fig 4A**). While spontaneous degradation of MTCO1 proteins which are unable to be
234 associated with MTCO2 is normally expected, the unaffected steady-state levels of MTCO1

235 suggest the presence of stabilised MTCO1 subunits despite not being assembled into
236 functional holocomplexes. The loss of the fully assembled complex IV in $COA5^{KO}$ cells were
237 not only observed in BN-PAGE analysis but also shown in complexome profiling of the
238 $COA5^{KO}$ cells. Most strikingly, this has also been similarly observed in a two-dimensional
239 BN-PAGE of patient fibroblast cell line in the previous report which demonstrated elevated
240 levels of MTCO1 subcomplex but a marked decrease in complex IV holocomplex (Huigsloot
241 *et al.*, 2011). Despite this, the remaining OXPHOS complexes (complex I, II, III and V) were
242 unaffected except the unusual accumulation of a protein complex of about 70 kDa detected
243 with SDHA which corresponds to the size of the individual SDHA protein in $COA5^{KO}$ cell line.

244 To further infer the role of COA5 protein and its interacting partner, mitochondrial
245 complexome profiling was employed to dissect co-migrating mitochondrial OXPHOS
246 complexes in the $COA5^{KO}$ cell line in comparison to its isogenic control. Notably, the
247 knockout of COA5 protein was confirmed using this method despite the unavailability of a
248 robust antibody for western blotting. Most strikingly, complexome profiling of the $COA5^{KO}$ cell
249 line presented evidence of the implication of COA5 in early complex IV assembly, pinpointing
250 its involvement to the stage between MTCO1 maturation and incorporation of MTCO2 into
251 the early assembly intermediate (**Fig 6B**). This is supported by the following observations:
252 the accumulation of MTCO1-containing subcomplexes (ranging from approximately 100 to
253 300 kDa) which are absent in the isogenic control, (ii) the apparent absence of MTCO2
254 subunit and (iii) the loss of fully assembled complex IV (**Fig 6A**). Notably, higher molecular
255 mass complexes were shown containing complex IV subunits in $COA5^{KO}$ and could reflect
256 assembly of intermediates with the supercomplex S_0 scaffold (Fernández-Vizarra & Ugalde,
257 2022). However, these are more likely to be prohibitin complexes, which direct the free
258 complex IV subunits for degradation rather than supercomplex formation since complex IV
259 biogenesis was completely obstructed (**Fig 6A**) (Back *et al.*, 2002; Kohler *et al.*, 2023;
260 Steglich *et al.*, 1999).

261 Furthermore, the higher abundance of complex I subunits, which was also observed
262 in the SDS-PAGE analysis of COA5^{KO} cell lysates, suggest an accumulation of
263 supercomplex S₀ (CI+III₂) which could not form a full respirasome in the absence of CIV
264 holocomplexes. Additionally, the complete loss of supercomplex III₂+IV reinforced the impact
265 of COA5^{KO} resulting in complex IV loss, hence favouring the formation of supercomplexes
266 only containing complexes I and III₂ to mitigate the OXPHOS defect due to the absence of
267 complex IV. Lastly, the accumulation of free SDHA was not seen in the isogenic control. This
268 may either indicate an upregulation of SDHA as a compensatory mechanism due to the
269 OXPHOS defect or an accumulation of a co-migrating complex of SDHA with CII assembly
270 factors, such as SDHAF1 or SDHAF2 (Martínez-Reyes & Chandel, 2020).

271 Nevertheless, the question remains as to how the c.157G>C (p.Ala53Pro) COA5
272 variant affects mitochondrial CIV assembly. The variant likely affects the CX₉C motifs of the
273 encoded protein which has been associated with the MIA pathway for IMS localisation
274 despite contradicting theories for its yeast counterpart (Bragoszewski *et al.*, 2013; Gladysck *et al.*,
275 2021; Herrmann & Köhl, 2007; Khalimonchuk *et al.*, 2008; Longen *et al.*, 2009) (**Fig 1B**).
276 The replacement of alanine by proline could potentially introduce a kink to the alpha helices
277 of the protein and consequently hampering correct folding of the protein to facilitate its import
278 (von Heijne, 1991). Consequently, verifying the submitochondrial localisation of COA5
279 protein would be fundamental in further investigation to inform its functional role associated
280 with an early stage of CIV assembly. Nevertheless, structural studies of the impact of the
281 single amino acid change in COA5-encoded protein could also be informative for its potential
282 impact on protein folding and subsequent effect onto its correct localisation within the
283 mitochondria.

284 If the COA5 protein is localised to the IMS, as of most mitochondrial proteins with
285 twin CX₉C motifs, it will most likely be involved in the delivery or incorporation of copper
286 atoms into complex IV which takes place in IMS. According to STRING ('**S**earch **I**ool for
287 **R**etrieval of **I**nteracting **G**enes/**P**roteins'; <https://string-db.org/>), COA5 protein is predicted to

288 interact with protein partners involved in mitochondrial protein import into IMS and COX
289 copper centre integration, though mostly based on text mining rather than experimental data.
290 Besides, the twin CX₉C motifs have also been linked to Cu(I) binding activity through the
291 reduction of disulphide bonding between the cysteine residues, especially for characterised
292 protein involved in COX maturation (Horng *et al*, 2004; Horng *et al*, 2005; Stroud *et al*, 2015).
293 Interestingly, Nývltová and colleagues also suggested a role for COA5 in the stabilisation of
294 what the authors termed ‘metallochaperone complexes’, comprising COX-specific copper
295 chaperones and haem biosynthesis enzymes required for the maturation and assembly of
296 COX subunits (Nývltová *et al*, 2022). Although beyond the scope of this manuscript, future
297 experiments should focus on interrogating a direct or indirect role of the COA5 protein in the
298 copper metalation of the MTCO2 subunit which, when affected, leads to destabilisation and
299 eventual degradation of the MTCO2 subunit.

300 Nevertheless, the possibility for the role of COA5 in the mitochondrial matrix should
301 not be eliminated before its submitochondrial localisation is confirmed. Recently, Peker and
302 colleagues demonstrated a two-step mitochondrial import pathway where substrates of the
303 disulphide relay system, including twin CX₉C protein family, rely on oxidative folding through
304 the MIA pathway in the IMS prior to their transport into the matrix (Peker *et al*, 2023). Matrix
305 localisation of the protein, however, would point towards an involvement in complex IV
306 biogenesis at the RNA or protein levels. A potential hypothesis is that COA5 could act as a
307 translation factor for MTCO2 expression, similar to the involvement of TACO1 and
308 MITRAC12 (otherwise known as COA3) proteins in the translational regulation of MTCO1
309 protein synthesis (Mick *et al*, 2012; Richman *et al*, 2016; Weraarpachai *et al*, 2009).
310 Moreover, COA5 could also represent a chaperone or stabilising factor for the MTCO2
311 subunit to facilitate its incorporation into MTCO1-containing subcomplex and therefore
312 impacting synthesis and stability of the MTCO2 protein specifically.

313 In conclusion, this study provides insights into a distinct mode of pathological
314 complex IV assembly caused by the assembly factor COA5 which specifically disrupts the

315 transitional stage between MTCO1 maturation and MTCO2 incorporation. We present
316 functional evidence to support a role for human COA5 protein in the early stage of complex
317 IV assembly, corroborating its pathogenicity that can contribute to isolated complex IV
318 deficiency. This warrants further investigation to uncover the structural and functional role of
319 COA5 with new insights into understanding its specific involvement in complex IV biogenesis.

320

321 **Materials and Methods**

322 ***Whole Exome Sequencing***

323 Trio WES (<https://www.exeterlaboratory.com/genetics/genome-sequencing/>) was conducted
324 at the Exeter Genomics Laboratory as previously described (Chen *et al.*, 2023).

325 ***Histopathological and Biochemical Analyses***

326 10 µm of frozen skeletal muscle sections were used in each assessment. For
327 histopathological studies, H&E staining was employed to determine muscle morphology
328 while sequential COX and SDH histochemistry was used to assess COX activity in muscle
329 fibres. Spectrophotometric measurements of OXPHOS enzyme (complexes I-IV) activities
330 were conducted as described in (Taylor *et al*) relative to citrate synthase activity. Quadruple
331 immunofluorescence assays were carried out by measuring NDUFB8 (CI) and MTCO1
332 (Reddy *et al*) protein abundance against mitochondrial mass marker, porin using in-house
333 analysis software as outlined in (Taylor *et al.*).

334 ***Cell Culture***

335 Patient and age-matched control fibroblasts, as well as U2OS cells, were cultured in High
336 Glucose Dulbecco's Modified Eagle Media supplemented with 10% fetal bovine serum, 1X
337 non-essential amino acids, 50 µg/ml penicillin, 50 µg/ml streptomycin and 50 µg/ml uridine.

338 ***SDS-PAGE***

339 Cell pellets were harvested when reaching 80-90% confluency and resuspended in lysis
340 buffer (50 mM Tris-HCl (pH 7.5), 130 mM NaCl, 2 mM MgCl₂, 1 mM
341 phenylmethanesulphonyl fluoride, 1% (v/v) Nonidet™ P-40 and 1X EDTA free protease
342 inhibitor cocktail). The resuspended cell pellets were incubated on ice for 10 minutes, before
343 harvesting the resultant supernatant from centrifugation at 500 g at 4°C for 5 minutes and
344 the protein concentrations were determined using Bradford assay.

345 Skeletal muscle homogenates were prepared by grinding 20 mg of frozen muscle section
346 into powder using pestle and mortar in liquid nitrogen and resuspended in
347 radioimmunoprecipitation (RIPA) buffer containing 1% Igepal, 1.5% Triton-X-100, 0.5%
348 sodium deoxycholate, 10mM β -mercaptoethanol, 0.1% SDS, 1 mM PMSF and 1X EDTA-free
349 protease inhibitor cocktail. The resuspensions were subjected to a 45-minute incubation on
350 ice followed by three rounds of 15-second homogenisation. The soluble proteins were
351 extracted by centrifugation at 14 000g at 4°C for 10 minutes and protein concentrations were
352 estimated using Pierce™ BCA Protein Assay Kit.

353 40 μ g of protein extracts were resuspended in 1X Laemmli Sample Buffer and denatured at
354 either 95°C for 5 minutes or 37°C for 15 minutes. The samples were then subjected to 12%
355 SDS-PAGE with the Mini-Protean Tetra Cell system and transferred onto a methanol-
356 activated Immobilon-P Polyvinylidene Fluoride (PVDF) membrane using the Mini Trans-Blot
357 Cell system.

358 **BN-PAGE**

359 Cells were pelleted and resuspended in cell homogenisation buffer comprising of 0.6 M
360 mannitol, 1 mM EGTA, 10 mM Tris-HCL pH 7.4, 1 mM PMSF and 0.1 % (v/v) bovine serum
361 albumin (BSA). The cell suspensions were subjected to three rounds of 15x homogenisation
362 in Teflon glass homogenisers at 4°C with intermittent differential centrifugation at 400 g for
363 10 minutes at 4°C to separate cytosolic protein fraction. The mitochondrial fractions were
364 pelleted at 11 000 g for 10 minutes at 4°C and washed in cell homogenisation buffer without
365 BSA.

366 Approximately 40 mg of skeletal muscle sections were processed and homogenised in
367 Muscle Homogenisation Buffer (250 mM sucrose, 20 mM imidazole hydrochloride and 100
368 mM PMSF) and homogenised in Teflon glass Dounce homogeniser for 15 to 20 rounds at
369 4°C. The muscle homogenates were then pelleted at 20 000 g for 10 minutes at 4°C and

370 washed twice with Muscle Homogenisation Buffer before pelleting at 20 000 g for 5 minutes
371 at 4°C.

372 The final pellets were solubilised in 2% n-dodecyl β -D-maltoside (DDM) and subjected to
373 ultracentrifugation at 100 000 g for 15 minutes at 4°C and the supernatants were extracted
374 for protein concentration determination using Pierce™ BCA Protein Assay Kit. About 10 μ g of
375 mitochondrial protein complexes were loaded and separated in the precast Native PAGE™
376 4-16% Bis-Tris 1.0 mm Mini Protein Gel in the XCell SureLock Mini-Cell Electrophoresis
377 System based on manufacturer's protocol. The protein complexes were then
378 immobilised onto an Immobilon-P PVDF membrane using the MiniTrans-Blot Cell system.

379 ***Immunoblotting Analysis***

380 The membranes were blocked in 5% milk for an hour at room temperature before
381 immunoblotting with specific primary antibodies and corresponding HRP-conjugated
382 secondary antibodies as listed: OXPHOS cocktail (ab110411, Abcam), MTCO1 (ab14705,
383 Abcam), MTCO2 (ab110258, Abcam), COXIV (ab14744, Abcam), NDUF8 (ab110242,
384 Abcam), SDHA (ab14715, Abcam), UQCRC2 (ab14745, Abcam), ATP5A (ab14748, Abcam),
385 GAPDH (600004, ProteinTech), VDAC1 (ab14734, Abcam), Polyclonal Rabbit Anti-Mouse
386 Ig/HRP (P0161, Dako) and Polyclonal Swine Anti-Rabbit Ig/HRP (P0399, Dako).

387 Finally, resultant signal was detected using SuperSignal™ West Pico PLUS
388 Chemiluminescent Substrate (Thermo Scientific) and analysed with ChemiDoc® XRS+
389 Imaging Systems and Image Lab Software (BioRad).

390 ***On-beads precipitation and protein digestion***

391 Cell pellets were lysed with 120 μ l RIPA buffer containing protease and phosphates inhibitors.
392 10 μ g of protein from all cell lysates were precipitated with 70% acetonitrile onto magnetic
393 beads (MagReSynAmine, Resyn Biosciences). The proteins were washed on the beads with
394 100% acetonitrile, 70% ethanol and then resuspended in 50 μ l 50mM ammoniumbicarbonate

395 containing 10mM DTT for reduction of cysteines. Samples were incubated at 37°C for
396 40min. Then, to alkylate proteins, 50µl of 30mM IAA in 50mM ammonium bicarbonate was
397 added and samples were incubated at RT in the dark for 30 minutes. 0.5µg trypsin was
398 added to each sample for overnight on-beads protein digestion at 37°C. The resulting
399 peptides were concentrated and desalted on EVOTIPS for mass spectrometry analysis
400 according to the standard protocol from EVOSEP.

401 ***LC-MS/MS analysis***

402 LC-MS/MS analysis was carried out using an EVOSEP one LC system (EVOSEP
403 Biosystems, Denmark) coupled to a timsTOF Pro2 mass spectrometer, using a
404 CaptiveSpray nano electrospray ion source (Bruker Corporation, Germany).

405 200 ng of digested peptides were loaded onto a capillary C18 column (15 cm length, 150 µm
406 inner diameter, 1.5 µm particle size, EVOSEP, Odense Denmark). Peptides were separated
407 at 40 °C using the standard 30 sample/day method from EVOSEP.

408 The timsTOF Pro2 mass spectrometer was operated in DIA-PASEF mode. Mass spectra for
409 MS were recorded between m/z 100 and 1700. Ion mobility resolution was set to 0.85–1.30
410 V·s/cm over a ramp time of 100 ms. The MS/MS mass range was limited to m/z 475-1000
411 and ion mobility resolution to 0.85-1.27 V s/cm to exclude singly charged ions. The
412 estimated cycle time was 0.95 s with 8 cycles using DIA windows of 25 Da. Collisional
413 energy was ramped from 20eV at 0.60 V s/cm to 59eV at 1.60 V s/cm.

414 Raw data files from LC-MS/MS analyses were submitted to DIA-NN (version 1.8.1) for
415 protein identification and label-free quantification using the library-free function. The UniProt
416 human database (UniProt consortium, European Bioinformatics Institute, EMBL-EBI, UK)
417 was used to generate library in silico from a human FASTA file. Carbamidomethyl (C) was
418 set as a fixed modification. Trypsin without proline restriction enzyme option was used, with

419 one allowed miscleavage and peptide length range was set to 7-30 amino acids. The mass
420 accuracy was set to 15ppm and precursor false discovery rate (FDR) allowed was 0.01 (1%).

421 LC-MS/MS data quality evaluation and statistical analysis was done using software Perseus
422 ver 1.6.15.0CRISPR/Cas9 Gene Knockout

423 Wildtype U2OS cells were resuspended in room-temperature Nucleofector Solution added
424 with Supplement from the Cell Line Nucleofector™ Kit V (Lonza) at a density of 1×10^6
425 cells per nucleofection reaction. COA5-targeting sgRNA (Sigma) was incubated at room
426 temperature with HiFi Cas9 nuclease at a 1:1.2 molar ratio to form ribonucleoprotein
427 complexes. The sgRNA sequence designed to mediate CRISPR/Cas9 knockout of the
428 COA5 gene is as follows: 5'-TTTTGAGTGATAAAAGATCAG-3'. The sgRNA-Cas9 RNP
429 complexes were nucleofected into wildtype U2OS cells on the Nucleofector™ 2b Device
430 (Lonza). Nucleofected cells were resuspended in growth media as outlined in Section 2.6.1
431 before transferring to a 6-well plate. The cells were incubated at 37°C, 5% CO₂ for 48 hours
432 before isolating into single cell clones using FACS Aria™ Fusion Flow Cytometer (BD
433 Biosciences) in four 96-well plates. Sanger sequencing chromatographs of the selected
434 single cell clones were analysed using Inference of CRISPR Edit (ICE) analysis (Synthego;
435 <https://ice.synthego.com/>) to identify isogenic controls and COA5 knockout cell line.

436 ***Complexome Profiling (BN-PAGE, Trypsin Digestion, LC-MS/MS, Quantification)***

437 Enriched mitochondrial proteins were extracted from COA5^{KO} and isogenic control cell lines
438 and solubilised with digitonin as described in (Giese et al., 2021). Equal amount of the
439 solubilised mitochondrial protein extracts were subjected to a 3 to 18% acrylamide gradient
440 gel (14cm x14cm) for BN-PAGE as outlined in (Wittig, Braun and Schägger, 2006). The gel
441 was then stained with Coomassie blue and cut into equal fractions then transferred to 96-
442 well filter plates. The gel fractions were then destained in 50 mM ammoniumb carbonate
443 (ABC) followed by protein reduction using 10 mM DTT and alkylation in 20 mM
444 iodoacetamide. Protein digestion was carried out in digestion solution (5 ng trypsin/μl in 50

445 mM ABC, 10% acetonitrile (ACN), 0.01% (w/v) ProteaseMAX surfactant (Promega), 1 mM
446 CaCl₂) at 37°C for at least 12 hours. After the recovery in the new 96-well plate, the peptides
447 were dried in a SpeedVac (ThermoFisher) and finally resuspended in 1% ACN and 0.5%
448 formic acid. Nano liquid chromatography and mass spectrometry (nanoLC/MS) was carried
449 out on Thermo Scientific™ Q Exactive Plus equipped with ultrahigh performance liquid
450 chromatography unit Dionex Ultimate 3000 (ThermoFisher) and a Nanospray Flex Ion-
451 Source (ThermoFisher). The MS data was analysed using MaxQuant software at default
452 settings and the recorded intensity-based absolute quantifications (iBAQ) values were
453 normalised to isogenic control cell line.

454

455 **Data Availability**

456 The mass spectrometry proteomics data for label-free whole cell proteomics and
457 complexome profiling produced in this study have been deposited to the ProteomeXchange
458 Consortium via the PRIDE partner repository (Perez-Riverol *et al*, 2022) and assigned the
459 dataset identifier PXD050891 and PXD053461 respectively.

460

461 **Acknowledgements**

462 RWT is supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the
463 Medical Research Council (MRC) International Centre for Genomic Medicine in
464 Neuromuscular Diseases (MR/S005021/1), the UK NIHR Biomedical Research Centre in
465 Age and Age-Related Diseases award to the Newcastle upon Tyne Hospitals NHS
466 Foundation, the Lily Foundation, LifeArc and the UK NHS Highly Specialised Service for
467 Rare Mitochondrial Disorders. RWT and MW are supported by the Pathology Society; RWT,
468 MW and AP are supported by Mito Foundation. JXT was supported by a PhD studentship
469 from the Lily Foundation and a Newcastle University Overseas Research Studentship award.
470 CBJ is supported by funding from the Academy of Finland (decision #336455), the Magnus
471 Ehrnroot Foundation and the Jane and Aatos Erkkö Foundation (#230004). The Proteomics
472 Core Facility, University of Oslo/Oslo University Hospital is supported by the Core Facilities
473 program of the South-Eastern Norway Regional Health Authority, and is a member of the
474 National Network of Advanced Proteomics Infrastructure (NAPI) which is funded by the
475 Research Council of Norway INFRASTRUKTUR-program (project number: 295910). IW is
476 supported by the Deutsche Forschungsgemeinschaft (DFG): SFB1531-S01, project number
477 456687919 and WI 3728/3-1, project number 515944830.

478

479 **Author Contributions**

480 **Conceptualization:** AP, MW, IW and RWT

481 **Data curation and formal analysis:** JXT, ACO, JM, LST, GM, SKS, AS, KS, LH, SH, TAN

482 **Clinical care of the family:** JD

483 **Supervision:** AP, MW, CBJ, IW and RWT

484 **Drafting the manuscript:** JXT, AP, MW and RWT

485 **Critical revision and editing of the manuscript:** all authors

486 **Funding acquisition:** AP, MW, IW and RWT

487 **Disclosure and competing interests statement:** The authors declare no conflicts of
488 interest.

489

490 **The Paper Explained**

491 **PROBLEM:**

492 A homozygous *COA5* variant was previously reported to cause a mitochondrial
493 cardiomyopathy phenotype but the role of the *COA5* protein is poorly defined despite being
494 proposed to be an assembly factor for cytochrome *c* oxidase (COX), an essential protein of
495 the mitochondrial respiratory chain.

496 **RESULTS:**

497 Through a series of biochemical experiments including LC-MS/MS-based complexome
498 profiling, our study showed that the human *COA5* protein is essential for the biogenesis and
499 incorporation of the MTCO2 subunit, specifically, to form functional COX holocomplexes.
500 Additionally, we present an additional case of *COA5*-related mitochondrial disease,
501 confirming the pathogenicity of the reported homozygous *COA5* variant that leads to
502 mitochondrial dysfunction.

503 **IMPACT:**

504 We have provided additional insights into the functional role of human *COA5* protein and its
505 specific implications on early-stage COX assembly, correlating to isolated COX deficiencies
506 observed in patients harbouring a pathogenic, homozygous *COA5* variant.

507

508

509 **Figure Legends**

510 **Figure 1 – Molecular genetics of the COA5 variant.**

511 **(A)** Partial family pedigree of COA5 patient showing segregation of the COA5 variant. **(B)**
512 Schematic representation of the COA5 gene (Ensembl) and its encoded protein (InterPro
513 and UniProt) illustrating the nucleotide or amino acid impacted by the COA5 variant. The
514 coiled coil-helix-coiled coil helix (CHCH) domain containing twin CX₉C motifs (purple stripes)
515 were illustrated in salmon pink. Amino acid residues at the position affected by the COA5
516 variant across different species were highlighted.

517 **Figure 2 – Histopathology findings of patient with COA5 variant**

518 **(A)** Histochemical analysis of skeletal muscle section from patient with haematoxylin and
519 eosin (H&E), cytochrome c oxidase (COX), succinate dehydrogenase (SDH) and sequential
520 COX-SDH histochemistry. Scale bar = 100 µm; magnification at 10x. **(B)** Quadruple
521 OXPHOS immunofluorescent assay of single skeletal muscle fibres from patient showing
522 immunoreactivity against complex I subunit, NDUF8 (x-axis) and complex IV subunit,
523 MTCO1 (y-axis) normalised with porin expression as mitochondrial mass marker. Each dot
524 corresponds to a single muscle fibre and beige colour corresponds to normal mitochondrial
525 mass. Muscle fibres with a z-score of less than -3 standard deviation are considered
526 deficient. Bold dashed lines represent the mean expression level in healthy muscle fibres. **(C)**
527 Spectrophotometric measurement of OXPHOS enzyme activities in patient fibroblasts (in red)
528 compared to mean activities in age-matched controls (in blue) shown as 100%. All
529 measurements were normalised to citrate synthase (CS) activity. Error bars represent
530 standard deviations of enzyme activities in control fibroblasts (*n*=8). Respiratory chain
531 enzyme activities in the patient which exceed control range are marked with an asterisk (*).

532 **Figure 3 – Immunoblotting analyses of COA5 patient-derived fibroblasts and skeletal** 533 **muscle biopsies.**

534 **(A)** SDS-PAGE and immunoblotting analysis of whole protein lysates from COA5 patient
535 fibroblasts (P) and age-matched controls (C1 and C2) showing steady-state levels of
536 OXPHOS complex subunits. GAPDH and SDHA were used as loading controls (*n*=3). **(B)**
537 BN-PAGE analysis of mitochondrial-enriched proteins from patient (P) against age-matched
538 controls (C1 and C2) immunodetected against specific OXPHOS complex subunits. SDHA
539 was used as loading control (*n*=3). **(C)** Western blot analysis of protein extracts from skeletal
540 muscle sections of patient (P) and controls (C1 and C2) with VDAC1 as loading control (*n*=1).
541 **(D)** BN-PAGE analysis of skeletal muscle mitochondrial extracts derived from patient (P) and

542 age-matched controls (C1 and C2) detecting all five OXPHOS complex subunits with SDHA
543 as loading control ($n=1$). **(E)** Label-free proteomic profiling of immortalised patient fibroblasts
544 with log-fold change in abundance compared to control. Each data point corresponds to the
545 mean of quadruplicate measurements of identified OXPHOS complex subunits (40 out of 44
546 CI subunits, 3 out of 4 CII subunits, 9 out of 10 CIII subunits, 11 out of 19 CIV subunits and
547 15 out of 20 CV subunits were analysed.)

548 **Figure 4 – Western Blot analyses of COA5^{KO} cell line against isogenic control.**

549 SDS-PAGE of whole cell lysates against **(A)** complex IV subunits including MTCO1, MTCO2
550 and COXIV ($n=2$) and **(B)** protein subunits of all five OXPHOS complexes using OXPHOS
551 cocktail antibody ($n=2$). GAPDH and/or SDHA were used as loading controls. **(C)** BN-PAGE
552 of mitochondrial-enriched lysates immunoblotted against all five OXPHOS complexes with
553 SDHA as loading control ($n=3$).

554 **Figure 5 – Complexome profiling identified decreased complex IV levels in COA5^{KO}
555 compared to wildtype (COA5^{WT}) isogenic control cell line.**

556 Isolated mitochondrial membranes were solubilised with digitonin and protein complexes
557 were separated by BN-PAGE followed by quantitative mass spectrometric analysis. The
558 quantitative data of identified individual subunits were summed up for each OXPHOS
559 complex and normalised to maximum appearance between both cell lines. The data are
560 presented as heat maps and 2D-plots, corresponding to protein components of individual
561 OXPHOS complexes. The size of the complexes ranges from 10000 kDa to 10 kDa (from left
562 to right). The corresponding complexes were highlighted above the heatmap and 2D-plots:
563 fully assembled complex IV holocomplexes (IV), complex III dimer (III₂), supercomplexes of
564 complex III dimers and complex IV (S_S) and supercomplexes containing complex I, complex
565 III dimer (S₀) and complex IV (S₁).

566 **Figure 6 - Accumulation of early-stage complex IV assembly intermediate**

567 **(A)** The following heatmap illustrates the distribution of complex IV subunits, assembly
568 factors and the prohibitin complex. The subunits and assembly factors of the assembly
569 modules are cultured as follows: MTCO1 module (green), MTCO2 module (purple), MTCO3
570 module (orange) and final subunit (black). The light blue arrows indicate subunits that co-
571 migrate with the prohibitin complex. **(B)** A schematic illustration of the sequential assembly
572 intermediates of the CIV holocomplex. Adapted from (Hock *et al*, 2020).

573 **Figure EV1 – Synthego Inference of CRISPR Edits (ICE) analysis of COA5 CRISPR
574 knockout and isogenic control cell lines.**

575 **(A)** A homozygous 7bp deletion (c.287_290+3del, p.Val61del) around the expected cut site
576 of the expected cut site of the *COA5*-targeting sgRNA (indicated with black dotted line) was
577 verified, generating a full knockout of the *COA5* gene. Sanger sequencing traces in the
578 bottom panel illustrate the deletion of seven bases in the *COA5*^{KO} cells compared to wildtype
579 sequence shown below which contains protospacer adjacent motif (PAM) site underlined in
580 red dotted line and the sgRNA binding site in black. **(B)** Wildtype sequence was confirmed
581 through Sanger sequencing in the isogenic control cell line selected from the cell population
582 that was nucleofected with Cas9 and sgRNA targeting the *COA5* gene.

583 **Figure EV2 – Mitochondrial complexome profiling of *COA5*^{KO} and wildtype (*COA5* WT)**
584 **isogenic control cell lines.**

585 The data are presented as a heat map, corresponding to protein components of individual
586 OXPHOS complexes. The size of the complexes ranges from 10000 kDa to 10 kDa (from left
587 to right). The corresponding complexes were highlighted above the heatmap as individual
588 subunits, fully assembled complex IV holocomplexes (IV), complex III dimers (III₂), small
589 supercomplex of complex III dimers and complex IV (S_s, III₂+IV) and supercomplexes
590 containing complex I, complex III dimers (S₀) and complex IV (S₁). Relative abundance of
591 each protein was represented from low to high according to colour scale illustrated on the
592 bottom right.

593 **Figure EV3 – Complex II assembly intermediates in *COA5* KO**

594 The relative protein abundance is presented as a heat map, corresponding to protein
595 components of complex II. The size of the complexes ranges from 10000 kDa to 10 kDa
596 (from left to right) and are given as native membrane (top scale) and soluble (lower scale)
597 protein calibration. The orange box indicates an assembly intermediate in the *COA5*^{KO} cell
598 line.

599

600

601

602


603 References

- 604 Ahmed ST, Alston CL, Hopton S, He L, Hargreaves IP, Falkous G, Oláhová M, McFarland R,
605 Turnbull DM, Rocha MC *et al* (2017) Using a quantitative quadruple immunofluorescent
606 assay to diagnose isolated mitochondrial Complex I deficiency. *Sci Rep* 7: 15676
- 607 Alahmad A, Nasca A, Heidler J, Thompson K, Oláhová M, Legati A, Lamantea E,
608 Meisterknecht J, Spagnolo M, He L *et al* (2020) Bi-allelic pathogenic variants in NDUFC2
609 cause early-onset Leigh syndrome and stalled biogenesis of complex I. *EMBO Mol Med* 12:
610 e12619
- 611 Alston CL, Heidler J, Dibley MG, Kremer LS, Taylor LS, Fratter C, French CE, Glasgow RIC,
612 Feichtinger RG, Delon I *et al* (2018) Bi-allelic Mutations in NDUFA6 Establish Its Role in
613 Early-Onset Isolated Mitochondrial Complex I Deficiency. *Am J Hum Genet* 103: 592-601
- 614 Back JW, Sanz MA, De Jong L, De Koning LJ, Nijtmans LG, De Koster CG, Grivell LA, Van
615 Der Spek H, Muijsers AO (2002) A structure for the yeast prohibitin complex: Structure
616 prediction and evidence from chemical crosslinking and mass spectrometry. *Protein Sci* 11:
617 2471-2478
- 618 Belevich I, Verkhovsky MI, Wikström M (2006) Proton-coupled electron transfer drives the
619 proton pump of cytochrome c oxidase. *Nature* 440: 829-832
- 620 Bragoszewski P, Gornicka A, Sztolsztener ME, Chacinska A (2013) The ubiquitin-
621 proteasome system regulates mitochondrial intermembrane space proteins. *Mol Cell Biol* 33:
622 2136-2148
- 623 Cabrera-Orefice A, Potter A, Evers F, Hevler JF, Guerrero-Castillo S (2022) Complexome
624 Profiling—Exploring Mitochondrial Protein Complexes in Health and Disease. *Frontiers in*
625 *Cell and Developmental Biology* 9
- 626 Chen W, Rehsi P, Thompson K, Yeo M, Stals K, He L, Schimmel P, Chrzanowska-
627 Lightowlers ZMA, Wakeling E, Taylor RW *et al* (2023) Clinical and molecular characterization
628 of novel FARS2 variants causing neonatal mitochondrial disease. *Mol Genet Metab* 140:
629 107657
- 630 Fernández-Vizarra E, Ugalde C (2022) Cooperative assembly of the mitochondrial
631 respiratory chain. *Trends Biochem Sci* 47: 999-1008
- 632 Gladysck S, Aras S, Hüttemann M, Grossman LI (2021) Regulation of COX Assembly and
633 Function by Twin CX(9)C Proteins—Implications for Human Disease. *Cells* 10
- 634 Herrmann JM, Köhl R (2007) Catch me if you can! Oxidative protein trapping in the
635 intermembrane space of mitochondria. *J Cell Biol* 176: 559-563
- 636 Hock DH, Robinson DRL, Stroud DA (2020) Blackout in the powerhouse: clinical phenotypes
637 associated with defects in the assembly of OXPHOS complexes and the mitoribosome.
638 *Biochemical Journal* 477: 4085-4132
- 639 Horng Y-C, Cobine PA, Maxfield AB, Carr HS, Winge DR (2004) Specific Copper Transfer
640 from the Cox17 Metallochaperone to Both Sco1 and Cox11 in the Assembly of Yeast
641 Cytochrome c Oxidase*. *Journal of Biological Chemistry* 279: 35334-35340
- 642 Horng Y-C, Leary SC, Cobine PA, Young FBJ, George GN, Shoubbridge EA, Winge DR (2005)
643 Human Sco1 and Sco2 Function as Copper-binding Proteins*. *Journal of Biological*
644 *Chemistry* 280: 34113-34122
- 645 Huigsloot M, Nijtmans LG, Szklarczyk R, Baars MJ, van den Brand MA, Hendriksfransen
646 MG, van den Heuvel LP, Smeitink JA, Huynen MA, Rodenburg RJ (2011) A mutation in


- 647 C2orf64 causes impaired cytochrome c oxidase assembly and mitochondrial cardiomyopathy.
648 *Am J Hum Genet* 88: 488-493
- 649 Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q,
650 Holzinger E, Karyadi D *et al* (2016) REVEL: An Ensemble Method for Predicting the
651 Pathogenicity of Rare Missense Variants. *Am J Hum Genet* 99: 877-885
- 652 Kadenbach B (2017) Regulation of Mammalian 13-Subunit Cytochrome c Oxidase and
653 Binding of other Proteins: Role of NDUFA4. *Trends Endocrinol Metab* 28: 761-770
- 654 Khalimonchuk O, Rigby K, Bestwick M, Pierrel F, Cobine PA, Winge DR (2008) Pet191 is a
655 cytochrome c oxidase assembly factor in *Saccharomyces cerevisiae*. *Eukaryot Cell* 7: 1427-
656 1431
- 657 Kirchberg K, Michel H, Alexiev U (2012) Net proton uptake is preceded by multiple proton
658 transfer steps upon electron injection into cytochrome c oxidase. *J Biol Chem* 287: 8187-
659 8193
- 660 Kohler A, Carlström A, Nolte H, Kohler V, Jung S-j, Sridhara S, Tatsuta T, Berndtsson J,
661 Langer T, Ott M (2023) Early fate decision for mitochondrially encoded proteins by a
662 molecular triage. *Molecular Cell* 83: 3470-3484.e3478
- 663 Lobo-Jarne T, Pérez-Pérez R, Fontanesi F, Timón-Gómez A, Wittig I, Peñas A, Serrano-
664 Lorenzo P, García-Consuegra I, Arenas J, Martín MA *et al* (2020) Multiple pathways
665 coordinate assembly of human mitochondrial complex IV and stabilization of respiratory
666 supercomplexes. *The EMBO Journal* 39: e103912
- 667 Longen S, Bien M, Bihlmaier K, Kloeppel C, Kauff F, Hammermeister M, Westermann B,
668 Herrmann JM, Riemer J (2009) Systematic analysis of the twin cx(9)c protein family. *J Mol*
669 *Biol* 393: 356-368
- 670 Martínez-Reyes I, Chandel NS (2020) Mitochondrial TCA cycle metabolites control
671 physiology and disease. *Nature Communications* 11: 102
- 672 McEwen JE, Hong KH, Park S, Preciado GT (1993) Sequence and chromosomal localization
673 of two PET genes required for cytochrome c oxidase assembly in *Saccharomyces cerevisiae*.
674 *Curr Genet* 23: 9-14
- 675 Mick David U, Dennerlein S, Wiese H, Reinhold R, Pacheu-Grau D, Lorenzi I, Sasarman F,
676 Weraarpachai W, Shoubridge Eric A, Warscheid B *et al* (2012) MITRAC Links Mitochondrial
677 Protein Translocation to Respiratory-Chain Assembly and Translational Regulation. *Cell* 151:
678 1528-1541
- 679 Muramoto K, Ohta K, Shinzawa-Itoh K, Kanda K, Taniguchi M, Nabekura H, Yamashita E,
680 Tsukihara T, Yoshikawa S (2010) Bovine cytochrome c oxidase structures enable O₂
681 reduction with minimization of reactive oxygens and provide a proton-pumping gate. *Proc*
682 *Natl Acad Sci U S A* 107: 7740-7745
- 683 Nývltová E, Dietz JV, Seravalli J, Khalimonchuk O, Barrientos A (2022) Coordination of metal
684 center biogenesis in human cytochrome c oxidase. *Nature Communications* 13: 3615
- 685 Peker E, Weiss K, Song J, Zarges C, Gerlich S, Boehm V, Trifunovic A, Langer T, Gehring
686 NH, Becker T *et al* (2023) A two-step mitochondrial import pathway couples the disulfide
687 relay with matrix complex I biogenesis. *Journal of Cell Biology* 222
- 688 Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S,
689 Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M *et al* (2022) The PRIDE database
690 resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids*
691 *Res* 50: D543-d552

- 692 Povea-Cabello S, Brischigliaro M, Fernández-Vizarra E (2024) Emerging mechanisms in the
693 redox regulation of mitochondrial cytochrome c oxidase assembly and function. *Biochem*
694 *Soc Trans* 52: 873-885
- 695 Reddy P, Ocampo A, Suzuki K, Luo J, Bacman SR, Williams SL, Sugawara A, Okamura D,
696 Tsunekawa Y, Wu J *et al* (2015) Selective elimination of mitochondrial mutations in the
697 germline by genome editing. *Cell* 161: 459-469
- 698 Richman TR, Spåhr H, Ermer JA, Davies SMK, Viola HM, Bates KA, Papadimitriou J, Hool
699 LC, Rodger J, Larsson N-G *et al* (2016) Loss of the RNA-binding protein TACO1 causes
700 late-onset mitochondrial dysfunction in mice. *Nature Communications* 7: 11884
- 701 Signes A, Fernandez-Vizarra E (2018) Assembly of mammalian oxidative phosphorylation
702 complexes I-V and supercomplexes. *Essays Biochem* 62: 255-270
- 703 Steglich G, Neupert W, Langer T (1999) Prohibitins regulate membrane protein degradation
704 by the m-AAA protease in mitochondria. *Mol Cell Biol* 19: 3435-3442
- 705 Stroud DA, Maher MJ, Lindau C, Vögtle F-N, Frazier AE, Surgenor E, Mountford H, Singh AP,
706 Bonas M, Oeljeklaus S *et al* (2015) COA6 is a mitochondrial complex IV assembly factor
707 critical for biogenesis of mtDNA-encoded COX2. *Human Molecular Genetics* 24: 5404-5415
- 708 Tay SK, Nesti C, Mancuso M, Schon EA, Shanske S, Bonilla E, Davidson MM, Dimauro S
709 (2004) Studies of COX16, COX19, and PET191 in human cytochrome-c oxidase deficiency.
710 *Arch Neurol* 61: 1935-1937
- 711 Taylor RW, Pyle A, Griffin H, Blakely EL, Duff J, He L, Smertenko T, Alston CL, Neeve VC,
712 Best A *et al* (2014) Use of Whole-Exome Sequencing to Determine the Genetic Basis of
713 Multiple Mitochondrial Respiratory Chain Complex Deficiencies. *JAMA* 312: 68-77
- 714 Vidoni S, Harbour ME, Guerrero-Castillo S, Signes A, Ding S, Fearnley IM, Taylor RW, Tiranti
715 V, Arnold S, Fernandez-Vizarra E *et al* (2017) MR-1S Interacts with PET100 and PET117 in
716 Module-Based Assembly of Human Cytochrome c Oxidase. *Cell Reports* 18: 1727-1738
- 717 von Heijne G (1991) Proline kinks in transmembrane alpha-helices. *J Mol Biol* 218: 499-503
- 718 Watson SA, McStay GP (2020) Functions of Cytochrome c oxidase Assembly Factors. *Int J*
719 *Mol Sci* 21
- 720 Weraarpachai W, Antonicka H, Sasarman F, Seeger J, Schrank B, Kolesar JE, Lochmüller H,
721 Chevette M, Kaufman BA, Horvath R *et al* (2009) Mutation in TACO1, encoding a
722 translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset
723 Leigh syndrome. *Nature Genetics* 41: 833-837
- 724 Wikström M, Krab K, Sharma V (2018) Oxygen Activation and Energy Conservation by
725 Cytochrome c Oxidase. *Chem Rev* 118: 2469-2490
- 726

A



B







A

H&E


COX

SDH


COX-SDH




B




C







A




B




C



A



B



A


Status [?] ✔ Succeeded	Guide Target [?] TGTA AAAAGATCAGTGGTAAG	PAM Sequence [?] TGG	Indel % [?] 100	Model Fit (R ²) [?] 1	Knockout-Score [?] 100
------------------------------------	---	----------------------------------	-----------------------------	---	------------------------------------

POWERED BY SYNTHEGO ICE


RELATIVE CONTRIBUTION OF EACH SEQUENCE (NORMALIZED)



EDITED SAMPLE 159 TO 224 BP



CONTROL SAMPLE 152 TO 217 BP



B


Status [?] ✔ Succeeded	Guide Target [?] TGTA AAAAGATCAGTGGTAAG	PAM Sequence [?] TGG	Indel % [?] 0	Model Fit (R ²) [?] 1
------------------------------------	---	----------------------------------	---------------------------	---

POWERED BY SYNTHEGO ICE


RELATIVE CONTRIBUTION OF EACH SEQUENCE (NORMALIZED)



EDITED SAMPLE 161 TO 226 BP



CONTROL SAMPLE 152 TO 217 BP



WT

COA5^{KO}

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.27.24312374>; this version posted August 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

